Effect of ezetimibe on plasma adipokines: a systematic review and meta‐analysis

Abstract

The results suggested that ezetimibe add-on to statin therapy is associated with an enhanced TNF-α-lowering effect compared with statin monotherapy. Owing to the emerging role of TNF-α in the pathogenesis of metabolic disorders, further investigations are required to unveil the translational relevance of this TNF-α-lowering effect.

Does green tea extract enhance the anti‐inflammatory effects of exercise on fat loss?

“…The global epidemic of obesity is accompanied by a variety of health complications, in large part due to the accumulation of excessive adipose tissue that results in an imbalance in the expression of hormones, pro‐ and anti‐inflammatory adipokines and cytokines . These specific fat‐related hormones mediate vascular changes in obesity, which is an important risk factor for diabetes mellitus, metabolic syndrome and cardiovascular diseases . Weight loss in overweight and/or obese people increases health span and quality of life while also improving clinical outcomes.…”

“…1,2 These specific fat-related hormones mediate vascular changes in obesity, which is an important risk factor for diabetes mellitus, metabolic syndrome and cardiovascular diseases. 3 Weight loss in overweight and/or obese people increases health span and quality of life while also improving clinical outcomes. Methods of weight loss include diet, physical activity, drug or herbal medicine therapy, and surgery.…”

Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials

“…Additional to these mechanisms, there is evidence showing that Lp(a) serves as an acute-phase reactant and its biosynthesis is augmented by inflammation 17–19 . Ezetimibe is known to possess anti-inflammatory activity and may therefore affect Lp(a) production 20,23 . The involvement of the LDL receptor (LDLR) in the catabolism and clearance of plasma Lp(a) has also been discussed 24,25 .…”

Effects of short‐term add‐on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients

“…Previous studies reported that combined ezetimibe (10 mg) and simvastatin (20 mg/8 or 12 wk) therapy did not alter adiponectinemia in nondiabetic HC patients, prediabetic HC subjects, and patients with MetS and vascular disease . In the same way, a recent meta‐analysis of 23 controlled trials did not suggest any significant effect on plasma concentrations of adiponectin, and other adipokines, such as leptin, PAI‐1, and IL‐6, was achieved by adding ezetimibe to statin therapy …”

“…20,21,29 In the same way, a recent meta-analysis of 23 controlled trials did not suggest any significant effect on plasma concentrations of adiponectin, and other adipokines, such as leptin, PAI-1, and IL-6, was achieved by adding ezetimibe to statin therapy. 30 Yet, treatment with ezetimibe (10 mg) and simvastatin (10 mg/12 wk, or 40 mg/4 wk) increased plasma levels of adiponectin in HC patients. 20,27 These results suggest that the addition of ezetimibe to statin therapy has differential effects on adiponectinemia depending on statin dosage and the duration of treatment.…”